CSI Market
Sign In | Register

Akari Therapeutics Plc (AKTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AKTX Annual Cash Flow →
Reviewing cash flow figures over time highlights how Akari Therapeutics Plc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-14.46
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss8.43
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.31
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.02
Increase Decrease In Values Of Deferred Shares And Liability Related To Stock Options And Warrants-
Financing Interest Expense-
Other Financial Services Costs-
Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss-0.04
Adjustments Accretion Of Debt Issuance Costs On Notes Payable And Notes Payable Related Party0.01
Gain On Settlement Of Current Liabilities-0.17
Gain Loss On Derivative Instruments Net Pretax-0.23
Income taxes-0.86
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.93
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other0.09
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.70
Discontinued operations0.00
Net Cash flow from Operating Activities-2.49
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale, Maturity and Collection of Short-term Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Purchase Of Letter Of Credit Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Proceeds from Collection of (Payments to Fund) Long-term Loans to Related Parties0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.10
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.03
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-5.26
Proceeds For Future Exercises Of Warrants To Purchase Shares-
Proceeds From Issuance Of Restricted Shares-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents5.26
Proceeds From Deposits Received For Share Subscriptions-
Proceeds From Issuance Of Shares Net Of Issuance Costs0.19
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.05
Effect of exchange rate on cash flow0.00
Discontinued operations2.77
Free Cash Flow-2.49
Total Cash Flow-2.44
4 historic quarters locked

Sign in to unlock the full Akari Therapeutics Plc cash flow history.

Sign In Create Free Account

About Akari Therapeutics Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-037730

Figures are derived from filed reports and may be restated. Historical data is subject to revision.